PAR ANNOUNCES AGREEMENT WITH VALEANT TO PROMOTE CESAMET

Par Pharmaceutical Companies, Inc. today announced that it has entered into an agreement with Valeant Pharmaceuticals North America to promote the antiemetic drug Cesamet(TM) (nabilone) capsules following approval by the U.S. Food and Drug Administration (FDA). Cesamet is a cannabinoid agonist for the treatment of chemotherapy-induced emesis (CIE). Valeant has received an approvable letter from the FDA for Cesamet and is awaiting final approval.

PR Newswire (http://sev.prnewswire.com/medical-pharmaceuticals/20051103/NYTH06503112005-1.html)